Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(15):1127; doi:10.1093/jnci/96.15.1127-a
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Articles by Travis, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zielinski, S. L.
Right arrow Articles by Travis, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

In Brief

Sarah L. Zielinski, Kate Travis

The first 10% of the full text of this article appears below.

New Drug May Overcome Imatinib Resistance

A second-generation small-molecule inhibitor may effectively overcome resistance to the cancer drug imatinib (Gleevec), a growing problem among patients with chronic myeloid leukemia (CML), according to a new study that tested the drug in mice and in human leukemia cells.

Imatinib attacks and blocks an enzyme called BCR-ABL that . . . [Full Text of this Article]

Rate of PSA Rise Associated With Risk of Death from Prostate Cancer

Committee Approves FY2005 Budget for NIH


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?